Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07. Submission of Matters to a Vote of Security Holders.

On June 7, 2017, Reata Pharmaceuticals, Inc. (the Company) held
its 2017 Annual Meeting of Stockholders (the Annual Meeting). As
of April 13, 2017, the record date for the Annual Meeting (the
“Record Date”), 13,991,575 shares of the Companys Class A
common stock (Class A Common Stock) and 8,374,032 shares of the
Companys Class B common stock (Class B Common Stock) were
outstanding and entitled to vote at the Annual Meeting.Holders of
Class A common stock were entitled to one vote per share held as
of the Record Date, and holders of the Company’s Class B common
stock were entitled to three votes per share held as of the
Record Date. A summary of the matters voted upon by the
stockholders and the final voting results for each such matter
are set forth below.

Proposal 1 Election of Directors to the Board

Each of the following persons was duly elected by the Companys
stockholders as a director for the term expiring in 2020, with
votes as follows:

Proposal 2 Ratification of Appointment of the Companys
Independent Registered Public Accounting Firm

The appointment of Ernst Young LLP as the Companys independent
registered public accounting firm for the year ending December
31, 2017, was ratified by the stockholders, with votes as
follows:

About Reata Pharmaceuticals, Inc. (NASDAQ:RETA)

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases. The Company’s lead product candidates include bardoxolone methyl, which is being studied in Phase III trial for the treatment of pulmonary arterial hypertension (PAH), associated with connective tissue disease (CTD-PAH), as well as a Phase II trial for the treatment of pulmonary hypertension due to interstitial lung disease (PH-ILD), and PAH, each of which are subsets of pulmonary hypertension (PH), Omaveloxolone, which is in Phase II clinical development for the treatment of multiple diseases, including Friedreich’s ataxia, mitochondrial myopathies and metastatic melanoma.